Stock analysts at StockNews.com started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.
Other analysts also recently issued reports about the company. HC Wainwright increased their price objective on ANI Pharmaceuticals from $50.00 to $53.00 and gave the company a “buy” rating in a report on Monday, March 13th. Guggenheim assumed coverage on ANI Pharmaceuticals in a report on Tuesday, February 28th. They issued a “buy” rating and a $55.00 price objective for the company. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.00.
ANI Pharmaceuticals Stock Performance
NASDAQ ANIP opened at $39.35 on Thursday. The company has a market capitalization of $687.25 million, a price-to-earnings ratio of -12.94 and a beta of 1.06. ANI Pharmaceuticals has a twelve month low of $22.31 and a twelve month high of $45.99. The stock has a fifty day simple moving average of $42.99 and a 200 day simple moving average of $39.14. The company has a quick ratio of 2.40, a current ratio of 3.46 and a debt-to-equity ratio of 0.91.
Institutional Trading of ANI Pharmaceuticals
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.
- Get a free copy of the StockNews.com research report on ANI Pharmaceuticals (ANIP)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.